Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Survey Study of Gastroenterologists’ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease
Laurie B. Grossberg, Konstantinos Papamichael, Joseph D. Feuerstein, et al.
Inflammatory Bowel Diseases (2017) Vol. 24, Iss. 1, pp. 191-197
Open Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael, Adam S. Cheifetz, Gil Y. Melmed, et al.
Clinical Gastroenterology and Hepatology (2019) Vol. 17, Iss. 9, pp. 1655-1668.e3
Open Access | Times Cited: 274
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases
Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, et al.
JAMA (2021) Vol. 325, Iss. 17, pp. 1744-1744
Open Access | Times Cited: 109
Infliximab in inflammatory bowel disease
Konstantinos Papamichael, Steve Lin, Matthew Moore, et al.
Therapeutic Advances in Chronic Disease (2019) Vol. 10
Open Access | Times Cited: 110
Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases
Konstantinos Papamichael, Erik H Vogelzang, Jo Lambert, et al.
Expert Review of Clinical Immunology (2019) Vol. 15, Iss. 8, pp. 837-848
Closed Access | Times Cited: 90
Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials
Marthe Kirkesæther Brun, Johanna Elin Gehin, K. H. Bjørlykke, et al.
The Lancet Rheumatology (2024) Vol. 6, Iss. 4, pp. e226-e236
Closed Access | Times Cited: 7
Therapeutic drug monitoring in inflammatory bowel disease
Konstantinos Papamichael, Adam S. Cheifetz
Current Opinion in Gastroenterology (2019) Vol. 35, Iss. 4, pp. 302-310
Open Access | Times Cited: 56
Best Practice for Therapeutic Drug Monitoring of Infliximab: Position Statement from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology
Dahham Alsoud, Dirk Jan A. R. Moes, Zhigang Wang, et al.
Therapeutic Drug Monitoring (2024) Vol. 46, Iss. 3, pp. 291-308
Closed Access | Times Cited: 5
Attitudes and Barriers Toward Antiretroviral Therapeutic Drug Monitoring Among Infectious Disease Providers
Hongmei Wang, Claudia Torres‐Farfan, Thomas P. Giordano, et al.
Medicina (2025) Vol. 61, Iss. 3, pp. 544-544
Open Access
Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohn’s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort
Diana M. Negoescu, Eva A. Enns, Brooke Swanhorst, et al.
Inflammatory Bowel Diseases (2019) Vol. 26, Iss. 1, pp. 103-111
Open Access | Times Cited: 43
A 3‐year prospective study of a multidisciplinary early proactive therapeutic drug monitoring programme of infliximab treatments in inflammatory bowel disease
José Germán Sánchez‐Hernandez, Noemí Rebollo, Ana Martín‐Suárez, et al.
British Journal of Clinical Pharmacology (2020) Vol. 86, Iss. 6, pp. 1165-1175
Open Access | Times Cited: 40
Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
Silvia Márquez-Megías, Ricardo Nalda‐Molina, Javier Sanz‐Valero, et al.
Pharmaceutics (2022) Vol. 14, Iss. 5, pp. 1009-1009
Open Access | Times Cited: 26
Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU)
Francisco Rodríguez‐Moranta, Federico Argüelles‐Arias, Joaquín Hinojosa del Val, et al.
Gastroenterología y Hepatología (2024) Vol. 47, Iss. 5, pp. 522-552
Open Access | Times Cited: 4
Advances in Therapeutic Drug Monitoring for Small-Molecule and Biologic Therapies in Inflammatory Bowel Disease
Christopher Ma, Robert Battat, Vipul Jairath, et al.
Current Treatment Options in Gastroenterology (2019) Vol. 17, Iss. 1, pp. 127-145
Closed Access | Times Cited: 39
Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?
Manar Shmais, Miguel Regueiro, Jana G. Hashash
Inflammatory Intestinal Diseases (2021) Vol. 7, Iss. 1, pp. 50-58
Open Access | Times Cited: 28
Therapeutic Drug Monitoring of Infliximab in Acute Severe Ulcerative Colitis
Benjamin L. Gordon, Robert Battat
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3378-3378
Open Access | Times Cited: 10
Barriers to optimizing inflammatory bowel disease care in the United States
Elizabeth Spencer, Sadeea Abbasi, Maia Kayal
Therapeutic Advances in Gastroenterology (2023) Vol. 16, pp. 175628482311696-175628482311696
Open Access | Times Cited: 8
Therapeutic drug monitoring in inflammatory bowel disease: A practical approach
Devendra Desai
Indian Journal of Gastroenterology (2024) Vol. 43, Iss. 1, pp. 93-102
Closed Access | Times Cited: 2
An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease
Rajan Patel, Gaurav Nigam, Raj Jatale, et al.
Indian Journal of Gastroenterology (2020) Vol. 39, Iss. 2, pp. 176-185
Open Access | Times Cited: 21
Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline
Letícia Kawano-Dourado, Eirik Klami Kristianslund, Dena Zeraatkar, et al.
BMJ (2024), pp. e079830-e079830
Closed Access | Times Cited: 2
Wide variation in the use and understanding of therapeutic drug monitoring for anti-TNF agents in inflammatory bowel disease: an inexact science?
Mark Samaan, Zehra Arkir, Tariq Ahmad, et al.
Expert Opinion on Biological Therapy (2018) Vol. 18, Iss. 12, pp. 1271-1279
Open Access | Times Cited: 20
UK National Survey of Gastroenterologists’ attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease
Gaurav Nigam, Shadab Nayeemuddin, Evangelos Kontopantelis, et al.
Frontline Gastroenterology (2020) Vol. 12, Iss. 1, pp. 22-29
Open Access | Times Cited: 16
<p>A nationwide utilization survey of therapeutic drug monitoring for five antibiotics in South Korea</p>
Rihwa Choi, Hye In Woo, Hyung‐Doo Park, et al.
Infection and Drug Resistance (2019) Vol. Volume 12, pp. 2163-2173
Open Access | Times Cited: 15
Dermatologists on the medical need for therapeutic drug monitoring of biologics in psoriasis: results of a structured survey
Lisa Schots, Lynda Grine, Rani Soenen, et al.
Journal of Dermatological Treatment (2020) Vol. 33, Iss. 3, pp. 1473-1481
Open Access | Times Cited: 13
Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost‐effectiveness analysis
Jiaqi Yao, Xinchan Jiang, Joyce H. S. You
Journal of Gastroenterology and Hepatology (2020) Vol. 36, Iss. 9, pp. 2397-2407
Closed Access | Times Cited: 13
A random forest model predicts responses to infliximab in Crohn’s disease based on clinical and serological parameters
Yong Li, Jianfeng Pan, Nan Zhou, et al.
Scandinavian Journal of Gastroenterology (2021) Vol. 56, Iss. 9, pp. 1030-1039
Open Access | Times Cited: 12
Page 1 - Next Page

Scroll to top